A new peer-reviewed systematic review and meta-analysis evaluating the effectiveness of allogeneic umbilical cord-derived stem cell therapy for knee osteoarthritis has been published by physicians and scientists from Longevity Medical Institute
Published in Stem Cell Research International, the study is titled “Allogeneic Umbilical Cord Mesenchymal Stromal Cells for Knee Osteoarthritis: Systematic Review and Meta-Analysis of Controlled Injection Trials,” and synthesises evidence from controlled clinical trials comparing umbilical cord-derived stem cell therapy with established injection therapies used to treat knee osteoarthritis.
Intra-articular corticosteroid and hyaluronic acid injections are among the most commonly used non-surgical treatment options for knee osteoarthritis, but many patients experience only temporary relief, creating continued interest in regenerative medicine approaches that can provide more durable clinical improvement.
The systematic review identified controlled human clinical trials evaluating intra-articular allogeneic umbilical cord-derived stem cell therapy and synthesised the available evidence using a random-effects meta-analysis.
Stem cell therapy demonstrated lower WOMAC pain scores at 12 months compared with active comparator injections. The direction of benefit remained consistent across studies using hyaluronic acid and corticosteroid comparator groups.
The analysis also found lower total WOMAC scores at 12 months among patients receiving stem cell therapy, supporting broader improvements in pain, stiffness, and physical function.
Dr Kirk Sanford, founder and CEO of Longevity Medical Institute and lead author of the publication, said, “One of the most important questions patients ask is not simply whether a treatment works, but how long the improvement will last. By systematically evaluating the available controlled clinical evidence, we found a consistent signal favouring umbilical cord-derived stem cell therapy for pain and functional outcomes through 12 months compared with established injection therapies.”
Differing from narrative reviews, systematic reviews and meta-analyses use predefined scientific methodology to evaluate and synthesise published clinical evidence. This review followed PRIMSA 202 reporting standards and focused exclusively on controlled human clinical trials comparing umbilical cord-derived stem cell therapy with active injection comparators.
The quantitative analysis included two controlled clinical trials using different comparator therapies. One trial evaluated repeated stem cell therapy against hyaluronic acid, while a separate randomised controlled trial evaluated stem cell therapy against intra-articular triamcinolone corticosteroid.
Despite the comparator therapies differing, the pooled-random-effects analysis demonstrated a consistent direction of benefit favouring stem cell therapy across both comparator subgroups.
Dr Félix Porras, medical director of Longevity Medical Institute and co-author of the publication, said, “Scientific progress depends on carefully evaluating the totality of the available evidence. While additional larger randomised controlled trials remain necessary, these findings contribute meaningful evidence supporting the continued investigation of umbilical cord-derived stem cell therapy as a potential treatment option for patients with knee osteoarthritis.”
The review also evaluated safety across the controlled studies in the quantitative analysis. No clear signal of severe treatment-related adverse events was identified. An additional Phase I study in the quantitative review further supported the feasibility and tolerability of repeated stem cell administration; however, the authors emphasise that larger controlled trials are necessary to better define long-term safety and optimal dosing strategies.
The authors concluded that controlled clinical trial evidence implies intra-articular allogeneic umbilical cord-derived stem cell therapy could provide durable improvements in knee osteoarthritis pain at 12 months compared with standard injection-based comparators. They further noted that while the current controlled evidence base remains limited, the consistent direction of benefit supports continued evaluation in larger randomised trials.
